Irbesartan Macleods Pharma

Irbesartan, the active ingredient in Irbesartan Macleods Pharma, is an Angiotensin II receptor blocker presented as an oral tablet of unspecified strength for oral use. It is employed to treat hypertension and diabetic nephropathy in adult patients.

GNH USA supplies Irbesartan Macleods Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Clients benefit from reliable supply chains, on‑time delivery, and dedicated technical support throughout the procurement process.

Irbesartan, an Angiotensin II receptor blocker, is used to manage disorders of the renin‑angiotensin system that affect blood pressure and kidney function.

Hypertension: reduces systemic vascular resistance, lowering blood pressure and decreasing the risk of cardiovascular events in patients with elevated blood pressure. Diabetic nephropathy: slows the progression of kidney damage by reducing intraglomerular pressure and proteinuria in patients with type 2 diabetes. Proteinuria: diminishes urinary protein excretion, providing renal protective effects in individuals with chronic kidney disease associated with hypertension.

Irbesartan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after the first doses or dose increases. - Headache: mild to moderate cranial pain occurring during therapy. - Fatigue: generalized tiredness or lack of energy. - Abdominal pain: discomfort or cramps in the stomach region.

Serious or Rare Side Effects: - Angioedema: rapid swelling of the face, lips, tongue or airway requiring emergency care. - Hyperkalemia: elevated blood potassium levels that can affect heart rhythm. - Acute renal failure: sudden loss of kidney function, indicated by rising creatinine and reduced urine output.

When prescribing Irbesartan, clinicians should consider several safety measures to minimize risks. - Monitor blood pressure: check regularly to ensure therapeutic effect and avoid hypotension. - Assess renal function: evaluate serum creatinine and eGFR before initiation and during treatment. - Check serum potassium: avoid hyperkalemia, especially when combined with potassium‑sparing agents. - Use caution in hepatic impairment: dose adjustment may be required in severe liver disease. - Avoid in pregnancy: drug safety is not established and may harm the fetus. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Irbesartan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren (in diabetes): combined use may increase risk of renal impairment, hyperkalemia, and hypotension. - Potassium‑sparing diuretics: may cause dangerous elevations in serum potassium. - ACE inhibitors: concurrent use can lead to additive effects on blood pressure and potassium. - Lithium: increased lithium levels may result in toxicity.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring. - Cyclosporine: can raise irbesartan plasma concentrations, necessitating dose adjustment. - Rifampin: induces metabolism, potentially reducing irbesartan effectiveness.